Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 agents possess promising therapeutic outcomes in treating type 2 d